Overview

A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers

Status:
Completed

Trial end date:
2009-03-27

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the pharmacokinetic profile of a single 500 mg dose of SRT2104 administered as an oral suspension and a capsule formulation to normal healthy male and female volunteers in both the fed and fasted state. The secondary objective is to assess the safety and tolerance of SRT2104 administered as an oral suspension and as a capsule formulation to healthy male and female volunteers in both the fed and fasted state.

Phase:

Phase 1

Details

Lead Sponsor:

Sirtris, a GSK Company

Collaborator:

GlaxoSmithKline